Don’t Mess with Success: U.S. Immunology Treaters Resistant to Switching Stable Humira Patients to Biosimilars, According to Spherix Global Insights
Adalimumab biosimilars hold potential to grow the overall biologic-treated population, but only if the cost savings translate to patients and